Biomarin Pharmaceutical Inc (BMRN)
Number of days of payables
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Payables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Number of days of payables | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
December 31, 2024 calculation
Number of days of payables = 365 ÷ Payables turnover
= 365 ÷ —
= —
The number of days of payables for Biomarin Pharmaceutical Inc is not provided for any of the reporting periods from March 31, 2020, to December 31, 2024. The lack of this specific financial metric makes it challenging to assess the company's payment practices and the efficiency of managing its accounts payable during this time frame. It is recommended that Biomarin Pharmaceutical Inc considers disclosing this information in future financial reports to allow for a more comprehensive analysis of its financial performance and working capital management.
Peer comparison
Dec 31, 2024
Company name
Symbol
Number of days of payables
Biomarin Pharmaceutical Inc
BMRN
—
Abbott Laboratories
ABT
49.95
AbbVie Inc
ABBV
36.53
ACADIA Pharmaceuticals Inc
ACAD
15.77
Alkermes Plc
ALKS
18.68
Amphastar P
AMPH
31.10
ANI Pharmaceuticals Inc
ANIP
33.22
Arcus Biosciences Inc
RCUS
45.00
Bristol-Myers Squibb Company
BMY
41.51
Catalyst Pharmaceuticals Inc
CPRX
26.83
Collegium Pharmaceutical Inc
COLL
6.21